TrialAdvances in therapy2026

First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study.

Zhenggang Ren et al.PubMed ↗Publisher ↗

No numbers read from the abstract.